FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068953213> ?p ?o ?g. }

• W2068953213 endingPage "1745" @default.
• W2068953213 startingPage "1741" @default.
• W2068953213 abstract "Bronchioloalveolar carcinoma (BAC), a subtype of non-small cell lung cancer, is a difficult disease to treat with low response rates with cytotoxic chemotherapy. Bortezomib, a proteasome inhibitor, has demonstrated objective responses in patients with BAC in early-phase clinical trials. We conducted a phase II study of bortezomib in patients with advanced-stage BAC.Patients with advanced BAC, adenocarcinoma with BAC features or BAC with adenocarcinoma features, and less than two prior regimens were eligible. Prior epidermal growth factor receptor (EGFR) inhibitor therapy was allowed. Bortezomib was administered intravenously at 1.6 mg/m on days 1 and 8 of every 21-day cycle until disease progression or unacceptable toxicity. The primary end point was response rate. The Simon two-stage design was used.Forty-two patients were enrolled, and the study was halted early for slow accrual. Patient characteristics were female 55%, median age 68 years, and Eastern Cooperative Oncology Group performance status of 0 and 1 in 31 and 11 patients, respectively. Twenty-six (62%) patients had received prior therapy with an EGFR inhibitor. A median of four cycles of therapy were administered. Objective responses were noted in 5%, whereas 57% had disease stabilization. The median progression-free survival and overall survival were 5.5 and 13.6 months, respectively. Grade 3 diarrhea and fatigue were noted in three and five patients, respectively.Bortezomib is tolerated well and is associated with modest anticancer activity in patients with advanced BAC, including patients who progressed on EGFR inhibitor therapy." @default.
• W2068953213 created "2016-06-24" @default.
• W2068953213 creator A5003826371 @default.
• W2068953213 creator A5015548619 @default.
• W2068953213 creator A5027165899 @default.
• W2068953213 creator A5036091074 @default.
• W2068953213 creator A5044249948 @default.
• W2068953213 creator A5044795397 @default.
• W2068953213 creator A5051283101 @default.
• W2068953213 creator A5063441489 @default.
• W2068953213 creator A5063904421 @default.
• W2068953213 creator A5064172508 @default.
• W2068953213 creator A5071524213 @default.
• W2068953213 creator A5075799959 @default.
• W2068953213 creator A5088178599 @default.
• W2068953213 date "2011-10-01" @default.
• W2068953213 modified "2023-10-16" @default.
• W2068953213 title "Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003)" @default.
• W2068953213 cites W114306914 @default.
• W2068953213 cites W1988083586 @default.
• W2068953213 cites W1996994323 @default.
• W2068953213 cites W2000044224 @default.
• W2068953213 cites W2019527474 @default.
• W2068953213 cites W2019693766 @default.
• W2068953213 cites W2021658870 @default.
• W2068953213 cites W2049674541 @default.
• W2068953213 cites W2053393533 @default.
• W2068953213 cites W2070790769 @default.
• W2068953213 cites W2074090791 @default.
• W2068953213 cites W2075954248 @default.
• W2068953213 cites W2091378741 @default.
• W2068953213 cites W2095673635 @default.
• W2068953213 cites W2099725888 @default.
• W2068953213 cites W2102119601 @default.
• W2068953213 cites W2122684890 @default.
• W2068953213 cites W2136951601 @default.
• W2068953213 cites W2139248078 @default.
• W2068953213 cites W2140766252 @default.
• W2068953213 cites W2153613476 @default.
• W2068953213 cites W2163479859 @default.
• W2068953213 doi "https://doi.org/10.1097/jto.0b013e318225924c" @default.
• W2068953213 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3220078" @default.
• W2068953213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21716143" @default.
• W2068953213 hasPublicationYear "2011" @default.
• W2068953213 type Work @default.
• W2068953213 sameAs 2068953213 @default.
• W2068953213 citedByCount "11" @default.
• W2068953213 countsByYear W20689532132012 @default.
• W2068953213 countsByYear W20689532132013 @default.
• W2068953213 countsByYear W20689532132014 @default.
• W2068953213 countsByYear W20689532132016 @default.
• W2068953213 countsByYear W20689532132020 @default.
• W2068953213 countsByYear W20689532132023 @default.
• W2068953213 crossrefType "journal-article" @default.
• W2068953213 hasAuthorship W2068953213A5003826371 @default.
• W2068953213 hasAuthorship W2068953213A5015548619 @default.
• W2068953213 hasAuthorship W2068953213A5027165899 @default.
• W2068953213 hasAuthorship W2068953213A5036091074 @default.
• W2068953213 hasAuthorship W2068953213A5044249948 @default.
• W2068953213 hasAuthorship W2068953213A5044795397 @default.
• W2068953213 hasAuthorship W2068953213A5051283101 @default.
• W2068953213 hasAuthorship W2068953213A5063441489 @default.
• W2068953213 hasAuthorship W2068953213A5063904421 @default.
• W2068953213 hasAuthorship W2068953213A5064172508 @default.
• W2068953213 hasAuthorship W2068953213A5071524213 @default.
• W2068953213 hasAuthorship W2068953213A5075799959 @default.
• W2068953213 hasAuthorship W2068953213A5088178599 @default.
• W2068953213 hasBestOaLocation W20689532131 @default.
• W2068953213 hasConcept C121608353 @default.
• W2068953213 hasConcept C126322002 @default.
• W2068953213 hasConcept C141071460 @default.
• W2068953213 hasConcept C143998085 @default.
• W2068953213 hasConcept C203092338 @default.
• W2068953213 hasConcept C2776256026 @default.
• W2068953213 hasConcept C2776364478 @default.
• W2068953213 hasConcept C2776694085 @default.
• W2068953213 hasConcept C2777478702 @default.
• W2068953213 hasConcept C2778367456 @default.
• W2068953213 hasConcept C2778822529 @default.
• W2068953213 hasConcept C2781182431 @default.
• W2068953213 hasConcept C31760486 @default.
• W2068953213 hasConcept C535046627 @default.
• W2068953213 hasConcept C71924100 @default.
• W2068953213 hasConcept C90924648 @default.
• W2068953213 hasConceptScore W2068953213C121608353 @default.
• W2068953213 hasConceptScore W2068953213C126322002 @default.
• W2068953213 hasConceptScore W2068953213C141071460 @default.
• W2068953213 hasConceptScore W2068953213C143998085 @default.
• W2068953213 hasConceptScore W2068953213C203092338 @default.
• W2068953213 hasConceptScore W2068953213C2776256026 @default.
• W2068953213 hasConceptScore W2068953213C2776364478 @default.
• W2068953213 hasConceptScore W2068953213C2776694085 @default.
• W2068953213 hasConceptScore W2068953213C2777478702 @default.
• W2068953213 hasConceptScore W2068953213C2778367456 @default.
• W2068953213 hasConceptScore W2068953213C2778822529 @default.
• W2068953213 hasConceptScore W2068953213C2781182431 @default.
• W2068953213 hasConceptScore W2068953213C31760486 @default.
• W2068953213 hasConceptScore W2068953213C535046627 @default.

• next